

Supplementary Table 9: List of human TNBC and MpBC patient tumor details including response to chemotherapy, percentage of vimentin staining and tumor classification.

| Patient ID | Metaplastic | Vimentin (%) | Pathologic Response | Subtype |
|------------|-------------|--------------|---------------------|---------|
| P01 | N | 1 | RCB - III | UNS |
| P02 | N | 0 | RCB - II | MSL |
| P03 | N | <1 | RCB - II | IM |
| P04 | Y | 5 | RCB - III | IM |
| P05 | N | 1 | RCB - I | LAR |
| P06 | N | 5 | RCB - I | UNS |
| P07 | N | 30 | pCR | IM |
| P08 | Y | 15 | RCB - II | IM |
| P09 | Y | 15 | RCB - II | UNS |
| P10 | N | 0 | RCB - II | LAR |
| P11 | Y | 90 | RCB - II | M |
| P12 | N | 10 | RCB - III | MSL |
| P13 | N | 10 | RCB - II | BL1 |
| P14 | N | 1 | RCB - III | BL2 |
| P15 | N | 0 | | IM |
| P16 | N | 0 | RCB - II | UNS |
| P17 | N | 75 | RCB - II | BL1 |
| P18 | Y | <1 | RCB - II | M |
| P19 | N | | RCB - II | BL1 |
| P20 | N | 2 | RCB - III | MSL |
| P21 | N | 0 | RCB - III | IM |
| P22 | Y | 60 | RCB - II | M |
| P23 | N | 50 | RCB - III | BL1 |
| P24 | N | | RCB - I | BL1 |
| P25 | Y | 95 | RCB - II | MSL |
| P26 | N | 0 | | LAR |
| P27 | Y | 90 | RCB - II | IM |
| P28 | N | 15 | RCB - III | BL2 |

| | |
|------------|----------------------------------|
| M* | Mesenchymal |
| MSL | Mesenchymal Stem-Like |
| BL1 | Basal-Like 1 |
| BL2 | Basal-Like 2 |
| LAR | Luminal Androgen Receptor |
| IM | Immunomodulatory |
| UNS | Unspecific |

| | |
|------------------|---|
| pCR | pathological Complete Response |
| RCB I-III | Residual Cancer Burden (I, II and III) |